Allogeneic hematopoietic stem cell transplantation in Hungary

被引:1
作者
Arpad, Batai [1 ]
Peter, Remenyi [1 ]
Marienn, Reti [1 ]
Aniko, Barta [1 ]
Laszlo, Gopcsa [1 ]
Lilla, Lengyel [1 ]
Eva, Torbagyi [1 ]
Zoltan, Csukly [1 ]
Eva, Karaszi [1 ]
Attila, Tordai [2 ]
Hajnalka, Andrikovics [2 ]
Katalin, Balassa [2 ]
Szabolcs, Tasnady [1 ]
Tamas, Masszi [3 ]
机构
[1] Egyesitett Szent Istvan Szent Laszlo Korhaz, Budapest, Hungary
[2] Mol Diagnosztikai Lab, Orszagos Verellato Szolgalat, Budapest, Hungary
[3] Semmelweis Egyetem, Altalanos Orvostudomanyi Kar III, Belgyogyaszati Klinika, Budapest, Hungary
关键词
hematology; allogeneic stem cell transplantation; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; CHRONIC MYELOID-LEUKEMIA; BLOOD; OUTCOMES; COMPLICATIONS; PROPHYLAXIS; RECIPIENTS; DONORS; INDEX;
D O I
10.1556/650.2017.30648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and aim: The publication summarizes the 2548 stem cell transplantations performed in the period of 1993-2015 in Szent LaszlA Hospital, Budapest and provides a detailed discussion of the 425 allogeneic transplantations during 2007-2013. Method: The analysis explains the major steps of the evolution of allogeneic stem cell transplantation and compares the results of the unique Hungarian allogeneic center. Results: The significant shift in the transplantation indications from chronic myeloid leukemia to myelodysplastic syndromes and the rising age of the recipients are in line with world wide tendencies. The latter one is the consequence of the introduction and improvement of the concept of reduced intensity conditioning regimens, originally arising from the idea of Endre Kelemen. The most limiting factor, the donor availability seems to be resolved with the use of a new immunomodulating regimen, the application of posttransplantation cyclophosphamide, which allows the transplantation through HLA barriers with haploidentical family donors with comparable results to the HLA matched volunteer unrelated donors. The above mentioned tendencies result the wider use of allogeneic stem cell transplantation less dependent from recipient age, comorbidities and even donor availability. Conclusions: The publication highlights the need of expanding the stem cell transplantation budget and the involvement of new centers in Hungary in allogeneic of stem cell transplantation.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 32 条
[1]   Hematopoietic-cell transplantation at 50 [J].
Appelbaum, Frederick R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15) :1472-1475
[2]   Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia [J].
Appelbaum, Frederick R. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (03) :279-284
[3]   Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].
Baccarani, Michele ;
Cortes, Jorge ;
Pane, Fabrizio ;
Niederwieser, Dietger ;
Saglio, Giuseppe ;
Apperley, Jane ;
Cervantes, Francisco ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Radich, Jerald ;
Simonsson, Bengt ;
Silver, Richard T. ;
Goldman, John ;
Hehlmann, Rudiger .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051
[4]   Bone Marrow Transplantation for Acquired Severe Aplastic Anemia [J].
Bacigalupo, Andrea .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (06) :1145-+
[5]   The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy [J].
Balassa, K. ;
Andrikovics, H. ;
Remenyi, P. ;
Batai, A. ;
Bors, A. ;
Kiss, K. P. ;
Szilvasi, A. ;
Rajczy, K. ;
Inotai, D. ;
Gopcsa, L. ;
Lengyel, L. ;
Barta, A. ;
Reti, M. ;
Tordai, A. ;
Masszi, T. .
BONE MARROW TRANSPLANTATION, 2015, 50 (10) :1321-1325
[6]   Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia [J].
Barta, A ;
Dénes, R ;
Masszi, T ;
Reményi, P ;
Bátai, A ;
Torbágyi, É ;
Sipos, A ;
Lengyel, L ;
Jakab, K ;
Gyódi, É ;
Réti, M ;
Földi, J ;
Páldi-Haris, P ;
Avalos, M ;
Pálóczi, K ;
Fekete, S ;
Török, J ;
Hoffer, I ;
Jakab, J ;
Váradi, G ;
Kelemen, E ;
Petrányi, G .
ACTA HAEMATOLOGICA, 2001, 105 (02) :64-70
[7]   Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor [J].
Bensinger, WI ;
Clift, RA ;
Anasetti, C ;
Appelbaum, FA ;
Demirer, T ;
Rowley, S ;
Sandmaier, BM ;
TorokStorb, B ;
Storb, R ;
Buckner, CD .
STEM CELLS, 1996, 14 (01) :90-105
[8]   Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups [J].
Deeg, H. Joachim ;
Bredeson, Christopher ;
Farnia, Stephanie ;
Ballen, Karen ;
Gupta, Vikas ;
Mesa, Ruben A. ;
Popat, Uday ;
Hari, Parameswaran ;
Saber, Wael ;
Sefte, Matthew ;
Tamari, Roni ;
Petersdorf, Effie W. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (11) :1883-1887
[9]   National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].
Filipovich, AH ;
Weisdorf, D ;
Pavletic, S ;
Socie, G ;
Wingard, JR ;
Lee, SJ ;
Martin, P ;
Chien, J ;
Przepiorka, D ;
Couriel, D ;
Cowen, EW ;
Dinndorf, P ;
Farrell, A ;
Hartzman, R ;
Henslee-Downey, J ;
Jacobsohn, D ;
McDonald, G ;
Mittleman, B ;
Rizzo, JD ;
Robinson, M ;
Schubert, M ;
Schultz, K ;
Shulman, H ;
Turner, M ;
Vogelsang, G ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956
[10]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304